Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Compound Kushen Injection + levofloxacin is a combination therapy consisting of **Compound Kushen Injection (CKI)**, a traditional Chinese medicine injection derived from the roots of Sophora flavescens and Smilax glabra, and **levofloxacin**, a synthetic third-generation fluoroquinolone antibiotic. CKI is reported to have immunomodulatory, anti-inflammatory, and antitumor activities, often explored as an adjunct to chemotherapy to enhance clinical responses and immune function. Levofloxacin acts primarily by inhibiting bacterial DNA gyrase and topoisomerase IV, enzymes crucial for DNA replication, thereby exerting bactericidal activity against a range of gram-positive and gram-negative bacteria. The combination may be used in specific settings such as infection prophylaxis or treatment during cancer therapies to leverage both antimicrobial and potential complementary immunomodulatory effects[1][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on compound kushen injection + levofloxacin.